ConcertAI’s TeraRecon Showcases New Clinical and AI Solutions Designed to Enhance Treatment Planning for Structural Heart Patients at TCT 2023

ConcertAI’s TeraRecon, a leader in advanced visualization and artificial intelligence (AI) for medical imaging, will showcase its latest innovations and cardiology solutions designed to strengthen clinical confidence, build efficiency throughout the care pathway, and improve cardiac care experiences at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco this week.

Innovation in the Intuition™ solution gives physicians the edge to deliver precise and timely diagnostic interpretations by semi-automating complex image post-processing through tailored advanced clinical workflows. Because it is designed to deliver clinical decision support throughout the enterprise, including radiology, cardiology, neurology, oncology, and vascular surgery, Intuition also enables cross-department consolidation and can eliminate redundant solutions.

The latest version of Intuition, 4.7, adds robust cardiovascular AV functionality through a dedicated Left Atrial Appendage (LAA) workflow, updated Transcatheter Mitral Valve Repair (TMVR) workflow, and various enhancements to streamline cardiac coronary imaging and pre-op planning. These tools provide interventionalists with enhanced visualizations, semi-automated measurements, flexible interaction capabilities, and interoperability designed to streamline procedural planning and eliminate the need for multiple AV solutions.

Cardiology Suite, powered with partners Us2.ai and Coreline Soft, aims to fully automate the analysis and interpretation of echocardiograms and chest CT exams to assess, monitor, and provide insights to help support clinicians in treatment decisions for cardiac patients. Through automated measurements and reports, these AI solutions can help reduce image interpretation times and improve workflows while maintaining accuracy and reducing variability between operators and devices.

Cardiology Suite applications on the Eureka Clinical AI platform are FDA and CE-cleared with additional regional clearances. For full availability of each algorithm, please reach out to TeraRecon. Learn more about the Eureka Clinical AI platform capabilities at www.terarecon.com/artificial-intelligence.

“We are excited to be kicking off the controlled release of FEops HEARTguide™ software in combination with our market leading AV software, Intuition, to enable physicians to better plan and, therefore, better treat patients with LAA closure devices,” said Dan McSweeney, President of TeraRecon. “With the addition of FEops’ advanced Digital Twin clinical AI solution, we are poised to provide clinicians with an unparalleled tool streamlining CT-based preoperative planning for structural heart interventions, leading to more informed decision-making.”

FEops HEARTguide is a unique cloud-based procedure planning solution in the structural heart, based on Digital Twin technologies. With the LAA occlusion workflow, FEops HEARTguide enables U.S. physicians to virtually model different implant positions and sizes of FDA approved LAA devices, aiding physicians in the selection of the optimal size and position for a specific patient. Established clinical evidence from the randomized controlled PREDICT-LAA trial has shown that FEops’ Digital Twin-based planning for LAA closure results in improved procedure efficiency and outcomes as compared to standard CT based planning.

Stop by booth #2241 on Tuesday, October 24, 2-4pm, or Wednesday, October 25, 2-4pm, to meet our newest collaborator and see their state-of-the-art FEops HEARTguide solution, the latest AI-powered device simulation to support preoperative planning procedures for LAA occlusion.

TeraRecon will also be hosting two physician-led presentations in booth #2241 during TCT 2023:

Tuesday, October 24, 12:30 PM – Dr. Serge C. Harb, MD, FACC will be presenting Cardiac CT in Planning Structural Interventions: A Case-based and Hands-on Approach.
Wednesday, October 25, 12:30 PM – Dr. Devi Nair, MD, FACC, FHRS will be presenting Novel Device Simulation for CT-based Preoperative Planning in LAA Closure.

Schedule a meeting or demo to learn more about these new technologies at #TCT23:
https://www.terarecon.com/tct-2023-meeting-request-0

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.